1. Sayegh, N, Swami, U, Agarwal, N. Recent advances in the management of metastatic prostate cancer. JCO Oncol Pract 2021: OP2100206, https://ascopubs.org/doi/pdf/10.1200/OP.21.00206
Google Scholar2. O’Keefe, DS, Bacich, DJ, Huang, SS, et al. A perspective on the evolving story of PSMA biology, PSMA-based imaging, and endoradiotherapeutic strategies. J Nucl Med 2018; 59: 1007–1013.
Google Scholar | Crossref | Medline3. Palamiuc, L, Emerling, BM. PSMA brings new flavors to PI3K signaling: a role for glutamate in prostate cancer. J Exp Med 2018; 215: 17–19.
Google Scholar | Crossref | Medline4. Paschalis, A, Sheehan, B, Riisnaes, R, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol 2019; 76: 469–478.
Google Scholar | Crossref | Medline5. Tagawa, ST, Milowsky, MI, Morris, M, et al. Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res 2013; 19: 5182–5191.
Google Scholar | Crossref | Medline6. Tagawa, ST, Beltran, H, Vallabhajosula, S, et al. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 2010; 116(Suppl. 4): 1075–1083.
Google Scholar | Crossref | Medline7. Tagawa, ST, Vallabhajosula, S, Christos, PJ, et al. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer. Cancer 2019; 125: 2561–2569.
Google Scholar | Crossref | Medline8. Rahbar, K, Ahmadzadehfar, H, Kratochwil, C, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 2017; 58: 85–90.
Google Scholar | Crossref | Medline | ISI9. Kulkarni, HR, Singh, A, Schuchardt, C, et al. PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the bad berka experience since 2013. J Nucl Med 2016; 57(Suppl. 3): 97S–104S.
Google Scholar | Crossref | Medline10. Weineisen, M, Schottelius, M, Simecek, J, et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med 2015; 56: 1169–1176.
Google Scholar | Crossref | Medline | ISI11. Hofman, MS, Emmett, L, Sandhu, S, et al. [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 2021; 397: 797–804.
Google Scholar | Crossref | Medline12. Sartor, O, de Bono, J, Chi, KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021; 385: 1091–1103.
Google Scholar | Crossref | Medline13. Kratochwil, C, Fendler, WP, Eiber, M, et al. EANM procedure guidelines for radionuclide therapy with 177 Lu-labelled PSMA-ligands (177 Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging 2019; 46: 2536–2544.
Google Scholar | Crossref | Medline14. Yadav, MP, Ballal, S, Sahoo, RK, et al. Radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Am J Roentgenol 2019; 213: 275–285.
Google Scholar | Crossref | Medline15. Ahmadzadehfar, H, Matern, R, Baum, RP, et al. The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving. Eur J Nucl Med Mol Imaging 2021; 48: 4067–4076.
Google Scholar | Crossref | Medline16. Ahmadzadehfar, H, Zimbelmann, S, Yordanova, A, et al. Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride. Oncotarget 2017; 8: 55567–55574.
Google Scholar | Crossref | Medline17. von Eyben, FE, Roviello, G, Kiljunen, T, et al. Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging 2018; 45: 496–508.
Google Scholar | Crossref | Medline18. von Eyben, FE, Kairemo, K, Paller, C, et al. Lu-PSMA radioligand therapy is favorable as third-line treatment of patients with metastatic castration-resistant prostate cancer. A systematic review and network meta-analysis of randomized controlled trials. Biomedicines 2021; 9: 1042.
Google Scholar | Crossref | Medline19. Hofman, MS, Violet, J, Hicks, RJ, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 2018; 19: 825–833.
Google Scholar | Crossref | Medline20. Hofman, MS, Emmett, L, Violet, JY, et al. TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603). BJU Int 2019; 124(Suppl. 1): 5–13.
Google Scholar | Crossref | Medline21. Ferdinandus, J, Eppard, E, Gärtner, F, et al. Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617. J Nucl Med 2017; 58: 312–319.
Google Scholar | Crossref | Medline22. Heck, MM, Tauber, R, Schwaiger, S, et al. Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Eur Urol 2019; 75: 920–926.
Google Scholar | Crossref | Medline23. Ahmadzadehfar, H, Essler, M. Predictive factors of response and overall survival in patients with castration-resistant metastatic prostate cancer undergoing 177 Lu-PSMA therapy. J Nucl Med 2018; 59: 1033–1034.
Google Scholar | Crossref | Medline24. Rahbar, K, Bögeman, M, Yordanova, A, et al. Delayed response after repeated 177 Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer. Eur J Nucl Med Mol Imaging 2018; 45: 243–246.
Google Scholar | Crossref | Medline25. Heinzel, A, Boghos, D, Mottaghy, FM, et al. Ga-PSMA PET/CT for monitoring response to 177 Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2019; 46: 1054–1062.
Google Scholar | Crossref | Medline26. Grubmüller, B, Senn, D, Kramer, G, et al. Response assessment using 68 Ga-PSMA ligand PET in patients undergoing 177 Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2019; 46: 1063–1072.
Google Scholar | Crossref | Medline27. Fanti, S, Goffin, K, Hadaschik, BA, et al. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging 2021; 48: 469–476.
Google Scholar | Crossref | Medline28. Yordanova, A, Linden, P, Hauser, S, et al. Outcome and safety of rechallenge [177 Lu] Lu-PSMA-617 in patients with metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2019; 46: 1073–1080.
Google Scholar | Crossref | Medline29. Violet, J, Sandhu, S, Iravani, A, et al. Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177 Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. J Nucl Med 2020; 61: 857–865.
Google Scholar | Crossref | Medline30. Deep, G, Panigrahi, GK. Hypoxia-induced signaling promotes prostate cancer progression: exosomes role as messenger of hypoxic response in tumor microenvironment. Crit Rev Oncog 2015; 20: 419–434.
Google Scholar | Crossref | Medline31. Ahmadzadehfar, H, Gaertner, F, Lossin, PS, et al. BRCA2 mutation as a possible cause of poor response to 177Lu-PSMA therapy. Clin Nucl Med 2018; 43: 609–610.
Google Scholar | Crossref | Medline32. Hofman, MS, Violet, J, Hicks, RJ, et al. 177Lu-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 2018;19: 825–833.
Google Scholar | Crossref | Medline33. Violet, JA, Jackson, P, Ferdinandus, J, et al. Dosimetry of Lu-177 PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pre-therapeutic imaging and ‘whole body’ tumor dosimetry with treatment outcomes. J Nucl Med 2019; 60: 517–523.
Google Scholar | Crossref | Medline34. Strosberg, J, El-Haddad, G, Wolin, E, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 2017; 376: 125–135.
Google Scholar | Crossref | Medline35. Emami, B, Lyman, J, Brown, A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991; 21: 109–122.
Google Scholar | Crossref | Medline | ISI36. Benua, RS, Cicale, NR, Sonenberg, M, et al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 1962; 87: 171–182.
Google Scholar | Medline37. Del Prete, M, Buteau, FA, Beauregard, JM. Personalized 177 Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. Eur J Nucl Med Mol Imaging 2017; 44: 1490–1500.
Google Scholar | Crossref | Medline38. Del Prete, M, Buteau, FA, Arsenault, F, et al. Personalized 177 Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging 2019; 46: 728–742.
Google Scholar | Crossref | Medline39. Garske-Román, U, Sandström, M, Fröss Baron, K, et al. Prospective observational study of 177 Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging 2018; 45: 970–988.
Google Scholar | Crossref | Medline40. Miyahira, AK, Pienta, KJ, Babich, JW, et al. Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. Prostate 2020; 80: 1273–1296.
Google Scholar | Crossref | Medline41. Kratochwil, C, Bruchertseifer, F, Rathke, H, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med 2018; 59: 795–802.
Google Scholar | Crossref | Medline42. Feuerecker, B, Tauber, R, Knorr, K, et al. Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA. Eur Urol 2021; 79: 343–350.
Google Scholar | Crossref | Medline43. Ghosh, A, Heston, WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004; 91: 528–539.
Google Scholar | Crossref | Medline | ISI44. Bakht, MK, Oh, SW, Youn, H, et al. Influence of androgen deprivation therapy on the uptake of PSMA-targeted agents: emerging opportunities and challenges. Nucl Med Mol Imaging 2017; 51: 202–211.
Google Scholar | Crossref | Medline45. Hope, TA, Truillet, C, Ehman, EC, et al. 68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience. J Nucl Med 2017; 58: 81–84.
Google Scholar | Crossref | Medline46. Rosar, F, Dewes, S, Ries, M, et al. New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide. Eur J Nucl Med Mol Imaging 2020; 47: 687–694.
Google Scholar | Crossref | Medline47